Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.)

Scopus

Scopus profile and journal metrics

This journal is indexed in Scopus. Use these metrics for a quick publishing snapshot, then open the Scopus page for the authoritative profile.

Scopus
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Indexed in Scopus since 2022
CiteScore 1.0
Indexed since 2022
First decision 7 Days
Submission to acceptance 45 Days
Acceptance to publication 14 Days
Acceptance rate 8%

SCImago

SCImago Journal Rank preview

Use SCImago when you want a quick visual view of the journal ranking profile and external discoverability signals.

Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) SCImago Journal & Country Rank

DOAJ

Directory of Open Access Journals listing

The DOAJ record is useful for readers, librarians, and authors who want a direct open-access directory entry for the journal.

DOAJ
Palestinian Medical and Pharmaceutical Journal (Pal. Med. Pharm. J.) Open directory record
Original full research article

Formulation, In-Vitro Characterization, And Antifungal Efficacy ‎of Itraconazole ‎Topical Niosomal Gel: Development and Microbiological Evaluation

Published
2025-02-26
Pages
345 - 350
Full text

Keywords

  • Niosomal gel
  • Sustained release ‎action
  • Antifungal drugs
  • Itraconazole

Abstract

Background: Itraconazole is an effective antifungal agent; however, improving ‎its formulation as a topical agent is necessary due to its limited skin penetration ‎and duration of action. The present study aims to improve the efficacy of ‎antifungal treatments for skin infections by developing and studying itraconazole ‎‎(TCZ) in a prolonged-release niosomal gel (NSM-Gel) formulation. ‎Methods: TCZ‑loaded NSM-Gel was formulated using a thin film hydration ‎technique utilizing various non-ionic surfactants (tweens and spans). The TCZ ‎niosomal gels' different formulae were assessed for pH, entrapment efficiency ‎‎(EE%), particle size (PS), and polydispersity Index (PDI). Formula (TN4), which ‎was selected as the best formula, was further examined for zeta potential (ZP), ‎in-vitro ‎release, scanning electron microscopy (SEM), physical stability study, ‎and in-vitro antifungal efficacy. Results: the EE% for the developed NSM-Gel is satisfactory (86.41 – 98.44%), ‎PS between 4.12 and 8.17 µm, and PDI between 0.22 and 0.39. The release of ‎TCZ from the NSM-Gel provided an appropriate prolonged release effect. TN4 ‎had an elevated EE% with a delayed release profile (100.00% ± 1.25% after ‎‎18hrs). The results revealed the existence of vesicles characterized by a spherical ‎morphology. Physical stability studies of formula (TN4) showed good physical ‎characteristics. Furthermore, TN4 demonstrated superior antifungal activity ‎against Candida albicans, as evidenced by a larger inhibition zone than the ‎commercial product Venzole® gel 1% (2.40 vs. 1.50 cm). ‎
Conclusions: This investigation demonstrated the applicability of the NSM-Gel ‎in achieving the expected prolonged release effect for transdermal TCZ ‎administration in healing fungal infections.‎. (Style=ANU_Abstract)

Article history

Received
2024-10-24
Accepted
2024-12-13
Available online
2025-02-26
بحث أصيل كامل

Formulation, In-Vitro Characterization, And Antifungal Efficacy ‎of Itraconazole ‎Topical Niosomal Gel: Development and Microbiological Evaluation

Published
2025-02-26
الصفحات
345 - 350
البحث كاملا

الكلمات الإفتتاحية

  • Niosomal gel
  • Sustained release ‎action
  • Antifungal drugs
  • Itraconazole

الملخص

Background: Itraconazole is an effective antifungal agent; however, improving ‎its formulation as a topical agent is necessary due to its limited skin penetration ‎and duration of action. The present study aims to improve the efficacy of ‎antifungal treatments for skin infections by developing and studying itraconazole ‎‎(TCZ) in a prolonged-release niosomal gel (NSM-Gel) formulation. ‎Methods: TCZ‑loaded NSM-Gel was formulated using a thin film hydration ‎technique utilizing various non-ionic surfactants (tweens and spans). The TCZ ‎niosomal gels' different formulae were assessed for pH, entrapment efficiency ‎‎(EE%), particle size (PS), and polydispersity Index (PDI). Formula (TN4), which ‎was selected as the best formula, was further examined for zeta potential (ZP), ‎in-vitro ‎release, scanning electron microscopy (SEM), physical stability study, ‎and in-vitro antifungal efficacy. Results: the EE% for the developed NSM-Gel is satisfactory (86.41 – 98.44%), ‎PS between 4.12 and 8.17 µm, and PDI between 0.22 and 0.39. The release of ‎TCZ from the NSM-Gel provided an appropriate prolonged release effect. TN4 ‎had an elevated EE% with a delayed release profile (100.00% ± 1.25% after ‎‎18hrs). The results revealed the existence of vesicles characterized by a spherical ‎morphology. Physical stability studies of formula (TN4) showed good physical ‎characteristics. Furthermore, TN4 demonstrated superior antifungal activity ‎against Candida albicans, as evidenced by a larger inhibition zone than the ‎commercial product Venzole® gel 1% (2.40 vs. 1.50 cm). ‎
Conclusions: This investigation demonstrated the applicability of the NSM-Gel ‎in achieving the expected prolonged release effect for transdermal TCZ ‎administration in healing fungal infections.‎. (Style=ANU_Abstract)

Article history

تاريخ التسليم
2024-10-24
تاريخ القبول
2024-12-13
Available online
2025-02-26